文献速递精神分裂症与精神病性障碍

经济激励改善精神病性障碍患者维持治疗依从性:Money for Medication 多中心开放标签随机对照试验

Financial incentives for improving adherence to maintenance treatment in patients with psychotic disorders (Money for Medication): a multicentre, open-label, randomised controlled trial.
PubMed 文献 · Lancet Psychiatry · 2017-01-01

在荷兰三家精神卫生机构开展的多中心、开放标签随机对照试验,纳入169例18-65岁精神病性障碍门诊患者,随机接受常规治疗加经济奖励(每接受一次长效抗精神病药注射奖励30欧元/月,若完全依从)或仅常规治疗12个月。

要点

  • 经济奖励可显著提高精神病性障碍患者长效抗精神病药注射的12个月依从性。
  • 干预停止后6个月随访,依从性获益仍维持但幅度减小。
  • 研究支持经济激励作为改善依从性的有效干预手段。

核心结论

  • 经济激励是改善精神病性障碍患者长效抗精神病药注射依从性的有效方法。
  • 干预停止后6个月随访期内依从性获益仍维持,但效应量减小。

研究设计与样本

  • 多中心、开放标签、随机对照试验,在荷兰三家精神卫生机构二级精神科服务中开展。
  • 纳入169例18-65岁、诊断为精神分裂症或其他精神病性障碍、处方或计划开始长效抗精神病药注射、正在接受门诊治疗的患者。
  • 按1:1计算机生成随机分组(区组大小4),按治疗中心、性别、共病物质使用障碍(无/有)和基线前4个月抗精神病药依从性(<50% vs ≥50%)分层。
  • 干预组接受12个月常规治疗加每次注射经济奖励(完全依从时每月30欧元),对照组仅常规治疗。
  • 主要结局为12个月干预期间用药占有比(MPR),即实际接受长效抗精神病药注射次数除以处方总次数;随后随访6个月不提供金钱奖励;采用意向性分析。

主要发现

  • 主要结局数据可获得155例(92%)患者。

关键数值与推荐

  • 干预组奖励方案:完全依从时每月30欧元,对应每次接受长效抗精神病药注射。

临床怎么用

  • 对于精神病性障碍需长效抗精神病药注射维持治疗的门诊患者,可考虑结合经济奖励以提高依从性。
  • 经济奖励停止后依从性获益仍可部分维持,但需关注长期效果。

局限性

  • 开放标签设计,患者、临床医生、访谈者和研究助理在分组后未设盲。
  • 随访期仅6个月,长期效果尚需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Provision of financial incentives is a promising intervention for improving adherence in patients taking antipsychotic medication. We aimed to assess the effectiveness of this intervention for improving adherence to antipsychotic depot medication in patients with psychotic disorders, irrespective of their previous compliance. METHODS: We did this multicentre, open-label, randomised controlled trial at three mental health-care institutions in secondary psychiatric care services in the Netherlands. Eligible patients were aged 18-65 years, had been diagnosed with schizophrenia or another psychotic disorder, had been prescribed antipsychotic depot medication or had an indication to start using depot medication, and were participating in outpatient treatment. Patients were randomly assigned (1:1), via computer-generated randomisation with a block size of four, to receive 12 months of either treatment as usual plus a financial reward for each depot of medication received (€30 per month if fully compliant; intervention group) or treatment as usual alone (control group). Randomisation was stratified by treatment site and suspected prognostic factors: sex, comorbid substance-use disorder (absent vs present), and compliance with antipsychotic medication in the 4 months before baseline (<50% vs ≥50%). Patients, clinicians, interviewers, and research assistants were masked to group allocation before, but not after, group assignment. The primary outcome was the Medication Possession Ratio (MPR), defined as the number of depots of antipsychotic medication received divided by the total number of depots of antipsychotic medication prescribed during the 12 month intervention period. Patients were followed up for 6 months, during which time no monetary rewards were offered for taking antipsychotic medication. We did analysis by intention to treat. This trial is registered with the Nederlands Trial Register, number NTR2350. FINDINGS: Between May 21, 2010, and Oct 15, 2014, we randomly assigned 169 patients to the intervention group (n=84) or the control group (n=85). Primary outcome data were available for 155 (92%) patients. At baseline, the mean MPR was 76·0% (SD 28·2%) in the intervention group versus 77·9% (28·5%) in the control group. At 12 months, the mean MPR was higher in the intervention group (94·3% [SD 11·3%]) than in the control group (80·3% [19·1%]), with an adjusted difference of 14·9% (95% CI 8·9-20·9%; p<0·0001). This difference was maintained throughout the 6 month follow-up period: mean MPR of 86·6% (SD 22·2%) in the intervention group versus 76·0% (22·7%) in the control group (adjusted difference 6·5%, 95% CI 2·0-10·9; p=0·047). INTERPRETATION: Financial incentives are an effective way of improving adherence to antipsychotic depot medication among patients with psychotic disorders. Further research is needed to study the long-term effects of this intervention. FUNDING: Dual Diagnosis Center.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Noordraven EL, Wierdsma AI, Blanken P, et al. Financial incentives for improving adherence to maintenance treatment in patients with psychotic disorders (Money for Medication): a multicentre, open-label, randomised controlled trial. Lancet Psychiatry. 2017. PMID: 28236956. doi:10.1016/S2215-0366(17)30045-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。